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The supply and use of essential drugs in Sub-Saharan Africa is
at best  inadequate  because of  inappropriate practices in  the
selection, procurement, storage,  distribution, and prescription of
drugs. This paper recommends solutions based on drug policies
implemented successfully in several African countries.
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Few people in Sub-Saharan Africa have access to  paper discusses procurement strategies  that have
essential drugs.  And where drugs are available,  resulted in savings in several countries.
they are inequitably distributed and improperly
used.  The main problems -- and possible solu-  Drugs are wasted due to poor storage
tions -- are:  conditions,  inadequate security, and deficient
inventory control systems.  Proper selection,
Drugs are distributed through the private  quantification, storage, and inventory manage-
sector, nonprofit organizations, and govcmments.  ment of drugs could alleviate this problem.
The private sector consists of a large proportion
of unqualified illicit peddlers of drugs who  Drugs are also wasted because of inappropri-
dispense adulterated or expired drugs without  ate and over-prescription, and noncompliance by
prescription.  Pharmacies run by qualified  patients.  Efforts to involve prescribers in using
pharmacists are a small minority.  Nonprofit  standard treatment schedules and to inform
organizations -- usually humanitarian, secular, or  patients about the proper use of drugs could
religious -- and public agencies run by govem-  result in improved efficiency.
ments also distribute drugs.
Africa has special characteristics in its land-
African countries do not have the capacity to  use pattems. population density, and road
produce the drugs they need.  Phannaceutical  infrastructure that affect the distribution of
industries in Africa depend on imported raw  drugs.  Counterfeit drugs and difficulties in
materials that are expensive when bought in  financing essential drugs are also serious prob-
small quantities.  It is generally cheaper to import  lems.  The advent of AIDS has presented new
generic drugs than to produce them locally.  The  challenges in the provision of essential drugs.
Thc PRE Working Paper Serics disseminates the findings of work under way in the Bank's Policy, Research. and External
Affairs Complex. An objectivc of the scries is to get thesc findings out quickly, even if presentations are Iess than fully
polished. The findings, interprctations, and conclusions in these papers do not necessarily represcnt official Bank policy.
Produced at the PRE Dissemination CenterWHO estmates  that worldwide,  as many  u  2.5 billon  people-half
the worls  population-hae  Uttle or no regular accs  to esaential drugs
(WHO,  1988b).  The 435 million people in sub-Saharan Aftica are even
wose  o0, since only one-third are thought to have access to essential drugs
(Annez 1).  TIs  paper will attempt  to review the causes of this situation.
Th  fiSt  pan  desrt.  -4 drug supply systems in  Africa, both  public and
private; the  second describes opponunities  for improving efficiency and
reducing  waste and gives evidence for the savings to be made; and the third
reviw  sever  issues of specific importance to Afria,  namely, geographic
and spatial constraints; the problem of counterfeit drugs; financing  of drug
supplis  and cost recovery  or "cost  sharing;"  and the impact of AIDS on drug
SUppis.
How much are African  countries actually  spending  on  drugs? Table
1 gives an estimate of annual per capita drug imports for eight countries in
Africa from 1982-84.
How does this compare with what is estimated to be needed for
adequate drug supply?  Table 2 provides  some data on  treatment costs by
level of health fcility from a variety of countries in Afrika  These are only
indicative, and  in some senses are  not comparable, as  in some of  the
countries drugs are locally  produced and therefore may be more expensive;
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- uojustea;  inacrrent terms (795Z-4).
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t  pOl ests  vai  greatly  from one county to another as we  lThese
fpre  do, however, e  an idea  of the relative  order of magnitude  required
to provde bask treatments  using  essential  dmgs  Whether  a given  amount
of drugs i *sufficient  depends  on coverage  of health servics, and on how
many  annual  contas  with  the halth services  for  some  form  of treatment  are
thought to be 'adequate.
Data on per capita drug consumption  may also overstate the
availability  of drugs in rural areas,  s  drugs  tend to *stick'  at central  levels
and in hospitals.  Unless  specific  measures  have  been  taken to ensure regular
availabity of drugs in rural health centen, as in Zambia,  Kenya,  Uganda,
Zimbabwe,  Tanzania and a  number of other countries,  it is likely that
virtually  no drugs  are reaching  the lower  level  health  facilities. In Tanzania
Table 2  Average  Costs per Treatment  Episode  at Various  Levels
in Several  African  Countries
(USS)
health  i  Hospital
Countly  Year  Village  Dispensary  Center  OPD
Kenya  1984  U.Z9  U.2U
Kenya  1985  0.50
Sudan  1985  Q15  032  032  0.59
Bwundi  1986  0.37  037
Gambia  1967  0.12  0.24  035  0.50
Guln-Blsaau  1987  031
Ugda  (a)  1988  0.29  0.29  0.29
(a) Represents  total number  of outpatient treatments,  without designation  -o level.
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in 197  prior to the introduction of a 'it'  stem  of drug distribution, the
nstonal  per capita expenditure was USt1.20. At the national teaching  hos-
pitaL however, the avwrage  expenditure  was  US$9, with a  much as USS13
in the ward which received private patients and senior offidals, but S5.90 in
the gcne  ward. But in rural dispensaries,  only $0.02  wa  spent per patient
(Yudkin, 1980). A similar  ture of mal-distribution within a facility  is re-
ported from Nigeria; one author reports that *drup and  other equipment
said to be out of stock in the general ward, meant for the masses,  are stock
fl;!  in the amenity ward" (Ityavar,  1988.)
EoDnomlc,  pographicaL and  cultural fators, thorefore,  all combine
to  reduce the  effectiv  access of  many Africs  to  basic  rugs,  in all
lkelihood exacerbating  the generally  high morbidity and  mortality observed
in Afica
Drug Distbution  Systems in Africa
Dus  are distributed in most Africn  countries  through  three
sysm; one priate  cDmmercida,  one private non-profit, and another public
or  goverment-run.  A  fourth  possibility is a  parastatal  agency  which
although  owned by the government  often operates along commercial  lines
Mme  reatve  imporunce of these varies greatly  from one country  to awther,
with the private commeral  setor  virtually non-existent in some and  the
gotvrment-run networ  nearly defunct in otbhea  The importance of the
prvate non-profit sector varie  greatly as well, with a  relatively greater
presence  in English-speaking  East Africa  and in the coastal countries of West
Afric.  BEach  of these will be descnbed briefly.
The Private  Pharmaceutical  Sector
It is customary to compare  drug distribution in public  and private
sectors  by the relative value of their sales or  throughput  This  may lead to
an underestimation of the volume of drugs distributed by the public sector,
however, as the private commercial  sector typially distnbutes brand-name
drugs which are usually 4-5 times more expensive than generic equivalents
(Szuba, 1984; Sepulveda-Alvarez,  1985).  In order to give a more accurate
picture of the volume  of drugs distributed by both public  and private sectors,
Table  3 presents the results of an adjustment by the relatively  conservative
factor of 2 to make public  sector value comparable to that of the private sec-
tor, enabling a comparison  of overall drug volume to be made. This shows
that for wevral Afian  countries, the value of dugs  distnbuted  by the public
sector is significantly  higher than the unadjusted value would indiate;  for
four of the six countries, the public sector acunts  for at kast  half of the
drup  distributed. Adjustment  by a factor of 3 would bring the public  sector
share to over two-thirds of the total in four of the countries Thi  of course
amumes that the public sector procures drugs which are lss expensive  than
those procured by the private  sector, which may  not be the cue  for all drugs
Most publc  sector drug agencies, however,  do purchase some part of their4
drup  in bulk, generic  form  In some case, the same drugp  purchased  in
bulk throg  compotitive  bidding  by the pubUc  sector are significntly
cheaper  than thoe purchased  directly  by  the private  pharmacies;  in Zaire,  the
same drug was purchased  by the public sector for las  than balf of the
priate  sector price (Gluchberg and Singer,  1982).
Private  sector  pharmaies in Africa  are  concentrated  in urban  areas.
For enmpk,  of a total of 542 pharmacess in 9 French-speakdng  West
Afrian  countries, 301 (56%) were loated  in  tJo  capital city (Scrip,
November  27, 1985)  In Mali, the World Bank project zone of Kita,
BDfoulabe,  ad  Kenieba  circles  (districts)  had 7% of Mali's  population,  but
only 13% of the Pharmacie  Populaire  du Mali's  (PPM)  sales  were made  in
that area  Half of the PPM's sales are in Bamako,  wre  10% of the
population  liv  (World  Bank,  1983).  While  the situation  in many  English-
speaki  countries  and particularly  in East Afica is somewhat  better, the
same  concentation of private  pharmacies  in urban  area pertains Even  the
pesoe  of phrmacie
Table 3.  Relative  Importance  of Public  and Private  Sector Drug Distribution
(1)  (2)  (3)  (4)  (5)
Public  Public
by Value  Ae,asted  as Percent  Private  Public
(Unadjusted)  Cotal  of Adjusted by Value  by Value
Coutry  (Percent)  --ercent)y  Total  (Percent)  (Percent)
Burkin Faso  64  36  72  136  53
Niger  57  43  86  143  60
Rwanda  77  23  46  123  37
Senegal  85  16  32  117  27
Zambia  57  43  86  143  60
Zimbabwe  50  50  100  150  67
a  Value  of public  sector  drugs  adjusted  to private  sector  prices  for comparison  by multiplication
by factor of 2
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may  not in itself  guarantee  access;  the nrban poor  are also prevented  from
having  acss  to drugs  due to the high prices  of drug available  through the
privte sector and the sbortages  of free or low-cost  drug available  in the
public  sector  facilities In Burkina  Faso  and Mali,  for example,  the price  of
French  brand-name  drugs  in private  pharmacies  was  fixed  at 15-2C0%  of the
retail prke in France,  despite  the very  much  lower  purchasing  power  of the
clients and the fact that reimbursement is virtually non-eistentL  A study in
Abidjan,  Ivory  Coast found  that the average  cost of a prescription  was  the5
eqivent  of 100  French franca (about USS17);  a similar study carried out
in Paris found the awvrage  prescription price was 112  French francs (Bessard
et. aL, IQ(  In Frane,  however,  in addition to income leveb being 15 times
greatew  than in  hvry  Coast, most (if not all) of this price would be reim-
bused  by Socal  Security.
What is a 'private pharnacy'  in the African coatext?  It may have
little in common with a 'pharmau  in the Western sens.  Pharmacists are
so few in number that in most countries it would not be possible to require
the  presence of a pharmacist in a pharmacy.  As a result, there  is some
indication that unliensed  private drug selers  are the targets for distributors
of counterfeit drup  (Atueyl, 1988). In Nigeria,  a survey of retail pharmacies
in Maiduguri, Borno State, found that there were 90 retail pharmacies in the
town.  Of these, 10 were 'ethical pharmacies' run by qualified pharmacists,
and the remainder  wer  *dry drug  peddler shops,  by unqualfied
oesons.  These had Ucense to sell only propriety  (non-prescription) medi-
cin  but in fact had a wide range of drugs availabk.  Many  were expired and
we  adulterations  of popular  drugs.  TMe drug peddlers often  had  an
'Ijaction  room' whe  customers judged to be 'safe' were taken. The public
appartly  did not distinguish between the two types of pharmacy,  and used
both a  cinics where they consulted and were given prescriptions and treat-
ent.  Health problek  for which they sought treatment were (in order)
malaria,  cuts,  eye pains,  general  body  pains,  dysentery/diarrhea, skin
Infection, abdominal pain, family planning, cough, chest pain, and venereal
dies  The most freqaent  treatment was antibiotics, especiaUy  injections;
antibiotica represented 35% of treatments given. The second most frequent
treatment was drug  for diarrhea  (not  ORS',  followed by treatment for
malria.  Th  reasons most frequently cited for seeking treatment at the
pharmacies wa  that treatment was expeditious, drugs were rarely out of
stock, and the drugs given were efficacious and often better than nospital
treatment (Igun, 1987).  In Africa, drug shops or peddlers are much more
common than pharmacies rn  by qualified pharmacists. VUlage  drug shops
are often patronized because they are close, not because they are considered
to  be  suitable.  In Saradidi, Kenya, people cited lack ot  transport and
distance to alternatives, and that they were open in emergencies,  as major
reasons for patronizing the drug shops.  Prior to introduction of a scheme
whereby  village health workers provided antimalarial treatments, 53% of the
people  obtained  their  antimalarial  treatments  from  a  shop,  and  the
shookeeper provided advice  on dosage,  etc. But when  antimalarial treatment
ws  available from the village health  worker, 85% of the people preferred
to get their treatment  there.  When the scheme was in place, use of the
shops declined significantly,  with 90% reporting that they  no longer used the
shops for antimalarial treatments (Mburu et. aL, 1987).
Another type of drug outlet is the ilicit drug seller  who does not
opcrate from a  fixed pharmacy premises.  In Pikine, a  suburb of Dakar,
Senegal, 102 ilLicit  drug sellers were identified and a sample of ten were
intervwed  in depth.  They  had set up in markets,  on street corners, or were
itineant.  On  average they had  14.5 clients per  day.  Drugs were sold
primarily for symptomatic treatment, with pain and fatigue accounting for
77% of visits; aspirin in combination or alone is part of more than half of6
sales, Other dmru sold for actual  cure  were prmarily antibiotia and anti-
malarals.  Antibiotms  induded  mainly tetracyie,  sulfaguanidine  for
diahea,  and isoniazid  (an antl-tubercuiwis  drug) for  cough. AntimalarFils
included  prlmarily  choroquine and amnvxaquine  Most people consulted
tee  sellhs beause  prices are low, rince the dru  are sold in small
amounts-one or two tablts.  Sucb a pratice may lad  to selction  of
reastant organism. Te  risk might  be small  gien  the fact  that these drug
are not sold often;  of the 147  consultations,  9% received  tetrayline,  7% an
atImalarld  and 1% sulfauanldine. Yet the value of dru  sold on the
street in this way  wa almost  as grat is that provided  through  official  public
drug  outlets (Fan,  1988)  IA  Cameroon,  informal  drug  sellr  were  popular
cspecally  with poor peopl, since unlike the registered  pharmadces,  they
would sl  drup  in any qmtity.  This worha to the advantage  of the
pharmacst,  who  sells  drugs  tO the informal  vendors  who  then undertake  the
uapoitable  part of the reil  trade for them (van der Geest, 1967).
Yet a  Wtird  type of drug seller is the tradtional healr  who uses
modern dru,  especially  antibiotics,  in his  practic. This is an increasingly
common  occufrence  in Afia  as well  as throughout  the developing  world
(Bedae  and Goubaud, 1985;  Haak and Hardon, 1988).
A  urher  priate  commercial  drug source is the sale of  drugs
piffred from  public  health facUities  by  health staft Ti  may  take tCe form
of an exta charge for government  drugs which  are supposeo  to be free,
'prvte  practice  in the afternoon  or evening  using  government  drugs,  or
fm  the sale  of drus  o  other selles  In many  countries,  the risk of getting
cauot  and the potential penalties  are ls  than the pig  to be made by
rn.moving  small amounts  of materials  and drugs  from the system,  primarily
for personal  use. Typically  everyone  does it", and pilferage  is merely  an
income  supplement,  which  people may  have  come  to thinlk  of as a perquisite
of their position. Yet even though  the scale  of individual  acts  of pilferage
is relatively  small ,several dollars or tens of dollars would typical  ee
involved),  in some countries,  pilferage  is so widespread  that its cosL.d
consk.erable. In Cameroon,  health service  personnel  sell enough of the
public  drugs  to be considered whoksalers'  since they  in turn sell to drug
vendors. Yet another  category  would  be the port workers  and customs  offi-
cials,  who  use their position  to obtain medicines  for sale  to others,  and thus
cDuld  be considered  wbolesalers  (van der Geest, 1987). In Kenya,  prior to
introduction  of the lit  system,  losses  were estimated  at 25%; these were
reduced  to  ess  than 5% when  the kit system  was  in operation (Ministry  of
Health, Kenya,  eL aL). A  similar  situation has been described  in Sierra
Leone (Bldsoe and Goubaud,  1965).
The fact  that so many  people  benefit  from the  system creates  grt
resitance to needed  improvements  and control procedures;  no one has an
incentive  to improve  logistics,  and the pressures  to maintain  the status quo
are considerablW  (van  der Geest,  1982) In Sierm  Leone,  the local  dispenser
realized  that he would  lose his livelihood  if WHO-recommended  oral rehy-
dration therapy  and malria treatments  were adopted,  and he sucefully7
preured  town leaders  to prevent  the health educators  ffom the hespital
from coming  back (Bledaoe  and Goubsud, 1985).
Tbe privte  non-proflit sector  X  quite  different, and  s  usually
operated  by  misionarIes  or other non-governmental  humantarian  organiza-
tios  such  Mdecins  sanu  frontieres,  Save  the Chilkden,  etc. In the best
of cawe,  the non-profit  sector  uses  private  sector  management techniques
in the pursuit of social goals.  They  ofti  purchase  their drugs overseas
through  spedal purbasing  agencies  su.6h  as ECHO,  IDA. or UNICEF in
some ces,  in bulk  and using generic  names  In a grwing  number  of
ouwtries they  are foming their  own  procurement  and distribution  abencies
to enable the differeat nionm  ad  organtions  to benefit from bulk
purcha  ad  consequently  lower  prces.  many  of these orpaizations
bave  to charge  a user fee  for their  servios to complement  any  support they
may  st  om  oversea  or from 'he poernment in form of a capitation fee
or a bed-day  subsidy,  they are eager  to kcep  prices  low  so  that utlization
do.  nOt  decline  due to vatients'  inability to pay the fee  In Kenya,  for
camp,  where missions  and NOas  ar  responsble  for about 25% of all
healt  car,  provided,  overpresatption and  asig  drug prices were
having  a srm  impact  on utilization.  Each  hospital  was purchasing  small
qntities  of a large number  of mostly brand-name  drus.  In ooperation
with WHO, the various  hospitals and church organizations created a drug
procu,rment  and distribution  agency  (MEDS). As a result, prices  dropped
and efficliecy  was improvd.(Hogerzeil  and  Moore, 1967)  A similar
orgsnItlo.  exists in Gh,n  (Christian Health Association  of Ghana,
CHAG) (.Iogerzeil  and  Lamberts,  1984)  and is being  contemplated  in a
number  of  other countries  including  Sierra  Leone,  Zambia,  Uganda,  and
Nigeris.
What  is the  contribution  of the private  sector  in the distribution  of
ential drugs?  As noted above, the  private non-profit sector is
increasingly  turning  to bulk generic  drugs,  in part to keep  their fees  low  and
thus  ensure their continued  financial  health.  The private  commercial
sector,  however,  has yet to play  a significant  role. Tbis is mainly  because
in most  African  countries where  private  pharmacies  operate,  the income  of
the pharmacist  or owner  is derived  from  a profit  margin calculated  on the
basis  of the wholesale  price. There is therefore  no incentive  to carry  low
prced essential  drugs. Indeed  many  such  incentives  have  backfired;  typically
the  tetdency has been to permtit  a lower margin  on already low-priced
esentil  drugs,  which  further reduces  the  pharmacist's  incentive  to carmy
these  drugs  If the private  commercial  sector  is to become  more  involved
in  distnbution  of essential  drugs,  new  pricing  mechanisms  will need to be
found to reverse  the pattern of innentives.
A related question  is the albcation of foreign exchange  between
publc and private  sectors. Inevitably,  in cases  of foreign  exchange  shortage,
the import  of  a  high-priced  product  precludes  the import  of a larger  volume
of a cheaper  equivalent  essential  drug. Health  benefit considerations  need
to be taken into account;  and the authorities  responsible  for allocation  cf
foreig exchange need to ensure that the basic  drug needs of the public
sector are met, whDe  remaining  aware  of the private sector's demanc.(C3tAmbas  and  Foster,  1986)  Both private  sector  importers and  the
Ministy of Health have a  responsibility  to use available  funds as efficiently
a  posibl  The ministry  of finance must support  rationalization efforts by
making  required foreign exchange available,  since intenational  competitive
bidding-usually  the most advtagous  method of procnement-is  out of the
question unles  the necessary  foreign exchapge  is availablc  It is aspecially
important for the public sector to avoid the necd for emergency purchases
from the local private  traders who have had privileged accs  to  foreign
emchange, whose prices typically  are as much as three times t&  interna-
tional market price.  (Catsambas and Foster, 1986)
Tw Public  Sector
Two types of publk drug distribution structure are commonly  found
In Atka,  and  may  exist side  by side in some  cauntrieL  One is known  in
English-speakling  countris  usually  as  Central Medical Stores (CMS) and in
precb-speaking  countries as  the  Pharmacie  d'approvisionnement  or
Phaappro'.  It is usualy wholly government owned, under the Ministry
of Health.  Although  some of these are poorly run and ineffident, in a
number  of  countries  they have been rehabilitated and are able to  provide
a fuHlly  stisfactory  service. The other type of  structure is the parastatal or
pan-public drug importing  and distributing enterprise, often a monopoly,
which is  partly  government owned and  usually administered under  a
ministry  other than the Ministry  of Health.  Typically  these  operate along
_im  il  line  and  depending on the depee  of gvernment intervention
in their affairs,  they are often  indistinguishable  from the commercial private
sector.  In most cases they are permitted to cver  most or aUl  of their  costs.
In some  cas  they also carry out manufacturing  or formulation activities  on
behalf  of the government. Several of these organizations maintain their own
network  of retail  pharmacies as well as selling drugs to the Ministry of
Health for distribution through its own health facilities.
In both cases, the typical  public sector drug supply system relies at
least in part on  the existing network of  health facilities as distribution
points.  Potentially, thereiore, the density of distribution points is as great
as  the density of overall health facilities coverage. In the  three circles  of
the western  region of Mali mentioned  above, for /-  unple,  there were only
3 pharmaces  but 21  dispensaries and 3 health f',aters, all of which could
serve as drug distribution points. The  typical  structwe of a drug import and
distnbution system  involes aUl  drugs transiting a central warehouse  and then
being  distributed either to  regional stores or to depots at regional hospitals
From  there, the drus  are distributed to lower  evel  health  facilities.
What problems does the public sector face in  distributing drugs
especially to rural areas?  One problem  is that typicaly, the public sector
relies  on  gnwernment  budgetary support  which is  uncertain and  often
insullicient, and is prevented from charging the ful  cost of its services. As
a result, it is often running a deficit.  This  in turn means that there is not9
enough money  to provide  the  quantity  of drug needed in the system  to
permit enough to  flw  dovn to al! levels; the 'pipeline' is not full.
Insuffcient wpreswure  of drup  flowing  through the system  means not
enough  b available  at tbe end point  Another constraint  is that the public
sector s responsible  for  reaching  all the population  and cannot content
itself  with serving  those  who are easiest  to reach,  or those whose incomes
aow  them to purchase  high-priced  drug.  Tbe average  costs  of providing
services  nrease as they  are extended  to more  remote areas  and to under-
soned populations,  and diseconomies  of scale  begin  to appear. (Ov.v,  1986)
A third problem is that typically,  low priority and  prestige are
attachod to drug supply  and more generally, logistic in public health.
Lagistics  has a sort of  negative  prestige  in that it is only important  when
It is  time to apportion the blame. Ministries  of health are often  run by
mei  doctors who may lack appreciation for  the  difficultie and
imporace of logistcs;  logistics  specialists,  usually  not medical  doctors,  may
not be viwed  as  professionals". Logistics  is not considered  a stepping
stone in a pubic halth  career.  In a number of countries, this most
Impoftant of posts has been given as a sln'sre  to  someone who is past
retirement  age  and hs little trining  or aptitude  for the job. (Foster,  1987)
Ti  may be in part  responsible  for the presence  of some degree of
corruption  and pilferage  in a  number of publc systems.  Suggested
mesures for  reducing  corruption  include  high-level  commissions  to conduct
inquiries,  cours  and seminars  to  heighten  awarness of the problem,  and
simplification  of  administrative  procedures  and strengthening  of financial
maagement.  (Gould and Amaro-Reyes,  1983).  Some countries  have
temporarily  solved  the problem  by  employing  expatriates,  who  are outside
of  the bureaucratic  culture  and have  no kinsluo  ties  to the local  population,
for seasitive posts
'Pilferage'  on the other hand, is usually  more widespread  but on a
much  smaller  scale. The main  remedy  for pilferage  is better management
controls,  including  punishment  of those  caught  pilfering.  In many  countries.
the risk of getting  caught  and the potential  penalties  are less  than the gain
to be made by removing  small amounts  of  material and drugs  from the
system,  primarily  for personal use. The fact that so many  people  benefit
from  the  system  creates  great  resistance  to needed  improvements  and control
procedures;  no one has an incentive  to improve  logistics,  and the pressures
to maintain  the status quo are  considerable.  (van der Geest, 1982).
What can be done to improve  the efficiency  of the  public  sector,
and to enhance the usefulness  of the private  sector?  The following
discussion  wil attempt to trace  the elements  of a rational  approach  to drug
supply. Areas  of complementarity  between  public  and private sectors  will
be  noted, as well as areas where the goals appear to be in  conflict.10
Improving Efficiency and Reducing Waste in Drug Supply
.Selecdon  and Quantification  of Dtgs
The staring  point  for an  esential  dus  polity  is the  careful
sekction and quantfication  of drug needs acrd1ng  to the  ealth needs of
the population to be served.  Selection invohl  balancing  considertions  of
com with  those of efficay, safety, aem of administration, and other  lcal
coiderationo  An cumple  of the range of costs of  treatment with various
compsrble  dru  is quito usde  to  aid in the section  process.  In 1975,
an anicle appeared  which used Tanzanian data to compare the prices of
treatments with various drugs  The author dIstIguisbhd  betwen  utype A
drus,  wc  are older, poen  drugs, and  often available in generic form;
and  'ype  BO  drugs,  invented more  recently and  still under  patent  and
avaiable  only under brand nams  and usually much more expensivem  Th
ngeS  betwen  the che  t (uswually  an older drug avilable  in generic
form)  and the  most expensie  brand-name drug were  quite  wide; for
mxapb,  anpalc  treatment with a brnd  of  ibuprofen was 150 times the
urt  of treatment with aspirin;  the range for tranquilizers wa  50.60 times
for hookm m,  130  times,  and for oral antibiotica,  10.50  times.  He made
the argument tha  unnecsay  use of more expensive drugs  exhausts the
drug budget and deprives tillow citizens of  needed treatment. (Speight,
1975)
A more detailed treatment of the subject was provided in 1980  with
the publication  by AMREF ot a manual on  therapeutic guidelines  which  was
later reorinted under the  tite,  Guidelines to Drmg  Usage. (Upunda et al,
1983)  in it  the authors compared the various drugs used for the major
diseases.  Although the coSts  are now out of date, the  relative comparisons
stil  remain vaLid. A few  of the cost comparisons are pres..nid  in Table 4.
Clearly the costs of different drugs need to be taken  into account
in selecting drugs  Expenditures  on  antibiotics are particularly  important in
Table  4. Cost Comparisons of Alternative Drugs
for Common Conditions
rerceni
Condition/courws  Lowest cost  USS  Highest cost  USS  Diflerence
arhrtis  (Wi)  aspirin  O.Z1  lbuprolen  1.8
ascrsis  (dose)  piperazine  0.08  mebendazole  0.60  750
hypenension  (yr)  reserpine  24.50  methyldopa  141.25  576
infammtion  (wk)  aspirin  0.21  naproxen  2.67  1271
epiepsy  (yr)  pbenyto.in  3.56  carbamazepine  219.83  6209
urnay"  tract in  (wk)  nitrofurantoin  0.46  ampkilin  2.80  609
otitis media (wk)  phenoxym.pen.  0.84  amodcillin  3.50  417
NB:  Prices in 19e2 USS.
Source: Upunda, Yudkln, and Brown, Guidelines to Drug Usage,  1983.11
many developing  cmintriep, so  particular care is called for  in selecting
antibiotic  for use at various levels of the health care  system. Countries
with high burdens of chronic  disase,  such as arthritis, epilepsy,  diabetes, and
hypertension,  need to py  p.  cular attention to the costs of drugp used,
since treatment for these conuitions is lifelong and  inevitably costly.
In addition to the decision as to which essential drug  is to be
recommenccd as the first line drug for a given condition, there is also the
decision as to whether  ion-essential drugs will be used, and if so, under
what  conditionLs One author conduded in TIailand  that while  enough
money was spent on drug,  the actual consumption of  needed drugs was in
most cases below 15% of the requirement,  while more expensive items,
indu4ing analgeias, diuretics, tranquilizers,  hormones, and antibiotics,  were
'viy-and  posibly wildly-overconsumed.' Between 1969 and  1976,  the
annual growth of consumption of psychotherapeutics and  diuretics were
189% and  154% respectively. (Sepuhteda-Alvarez,  1985).  In the Yemen
Arab  Republic  between 1993 and  1987,  as much as 20% of the drugs
budpet  was spent on drio4 human plasma and albumin injection, which are
not consdered to be vital drugs. (Van Haperen, 1988)  Clearly much can
be done to improve  decision-making  about which  drugs should be purchased
St -n  the overa  scarcity  of resources.
After the decision  has been made as to which  drugs are  needed, the
nr  cual  question cncerns  the quanw:. of  each drug which will be
required over a gien  perod,  usually  a year. While it may seem diMcult to
amve at a  good estimte,  methods have now been developed to make use
of available  morbWity  data and appropriate treatment  scheduls  in arriving
at a workable  timate. (WHO, 1988a)  Such estimates can be invaluable in
procurement, and can help a country to avoid such anomalies as have been
reported, such as the order of 46 years' worth of  consumption of a drug by
a corrupt officiaL (Yudkin, 1978)  However, such estimates are only as
good as the morbidity data on which they are based, and the linking of the
data  with the provision  of drugs could proVide  an incentive to  health staff
to improve the quantity of the data they  provide.
Excessive  stock levels  of low priority drugs tie up  needed funds and
run the risk of expiring  unused.  Surprisingly,  in view  of the overall scarcity
which prevails,  expiration of drugs is a major problem in many low-income
countrieS.  In Mauritania, the drug supply  authorities estimated that Slm
worth of expired drugs were on the shelves of the governmeut drug supply
organization.  On the assumption that this had accumulated over, say, 4
yeas, this mens  an annual wastage of S250,000. In 1986, the government
drup  budget was S1m, so the value of the  expired drugs represented about
25% of the totaL (WHO,  1986) In Liberia, of 318 drugs on the shelves, 44
were expired or unusabl.  On the assumption that their average value was
roughly equivalent, the wastage due to expiration was on the order of 15%.
(Managcment Ssiences for Health,  1984)
Similarly,  in Ghana, a World Bank-funded quantification  of drug
needs for the public sector, based on morbidity,  was recently carried out by12
the Ministry  of Health. The overall  estimated  needs  came  to approximately
US$4 milion  equivalent-only  half of what had actually  been spent on
drug.  The high  wastage  of drugs  was  confirmed  by  a  Bank-funded  audit of
drug stocks  throughout  the country-45% of the drup were  either expired
(33%)  or due to expire within  the next  six  months  (12%). In part this may
be due  to the introduction  of user charges  in 1985,  which has  reduced
utilization  of health facilities  signifcantly  and shifted  drug purchase  to the
private  sector,  ordering  of pharmaceuticals  for the pubic sector  has not yet
caught up  with the trend.
Stockouts  of high priority  drugs,  on the other hand, may  result in
costly  local  purchases  from  private  suppliers. Local  purchases  are  commonly
twice  or three times  the cost of imported  drugs,  and price differentials  of
up to 10 times have been reported. (See below,  'Procurementg.)
Once the drug needs have  been quantified,  it is a  relatively  easy
step to cost them and then establish  the  overall cost of drugs This link,
between estimating  and  costing drug needs, and using the results in
dscuuss  with the  financial authorities. is a  crucial step  towards
improving  the financing  of drug supplies.  Financial authorities-those
rspo8sib  for budget  allocations  and for release  of foreign  exchange-have
shown  themselves responsive  to such iron-clad  proof  and justification  of
needs In fact,  Zimbabwe  recently  used  its drug quantification  to obtain  an
agreement  from  the financial authorities  that the needed  foreign  exchange
would be made  milblb.
To Make or Buy?  Local Producion of Drugs
In 1982,  production  of pharmaceuticals  in Africa  was estimated  to
be worth  approximately  USS750  million,  accounting  for less  than 1%  of the
world total of USS  95  billion.(Scrip,  May  6, 1985) As much  of this was
done by  local affiliates  of foreip companies,  with production  of  active
ingredients  and research  taking place elsewhere,  this  may overstate the
extent  of local  production. African  countries  continue  to import  significant
quantities  of drugs from  Europe,  with 96%  of imports  coming  from  Europe
and only 0.7% from elsewhere  in Africa  in 1984. Africa  is an  important
market  for Europe,  with  an estimated  12.7%  of European  exports  going  to
Africa  By  comparison,  Latin American  regional  trade is more  important,
with 32% of  imports  coming  from within  the region  and only 49% from
Europe,  and 13% from North America.(WHO,  1988b)
This low level of pharmaceutical  production  activity in  Africa
conceals  an important  fact: virtually  all  Afrcan  countries  already  have
some installed  capacity  for drug formulation,  if not production. (Formula-
tion is the final stage  in drug  production,  such  as the tabletting,  packaging,
etc  of pharmaceutical  intermediates  produced  elsewhere.)  Yet most of
these fatories are operating significantly  below capacity,  and some are
closed  for long  parts of the year. The reasons  for  this situation  are complex13
and not  amenable to easy solutions.  In many cases, countries  decided to
proceed with Oshowpiece  pharmaceuticals production, while continuing to
import even basic goods such  as soap, canned fruit and preserves, bottles
and  plastic  packaging materials, bicycles,  and so  on.  Pharmaceutical
production was expected to provide a stimulus to development of ancillary
industries, such as chemicals, glasswae,  packaging,  etc.  Foreign exchange
savingp  were also expected to be significant and this alone was taken to be
justication  enough.  These  views were  encouraged  by a  number  of
development agencies  and financing  was relatively easy  to arrange; the result
is a number of uneconomic  factories in need of rehabilitation or closure.
A number of key assumptions were made about lcal  production of
pharmaceuticals which need to be reexamined in the light of experience  and
changes in the world market  for pharmceuticals, Fhlt,  the economic and
financal  analyses which were carried out  often used the  prices of the
brand-name drug which the oally  produced ones were expected to replace.
But in the last seven or so years, the  international trade in generic drugs
has  increased  substantially and  the  prices  have  fallen  significantly.
Febility  studies carried out in 1980,  therefore could not  have predicted
that drug prices would fail to a half or lss  of then current prices  But
now, gtven budget constraints  when faced with procurement  decisions,
goverments  have to  prefer the lss  expensive international generics to
localy-made equivalentsL The locally-made products were  rarely able to
compete with imported brand-name drugs and  therefore the private market
was also  losed  to them, unless  there  was heavy tariff protection or  an
outright ban on  import of products made loally.  (Foster, 1989)
A second assumption was that foreign exchange  savings would be
considerable.  It appears that raw materials and  interuediates  would be
cheaper imported in bulk. However, even raw materials are not necessarily
cheaper than the finished product; often the manufacturers  ignore very  small
orders or charge the price of their smallest packing unit  (often 100 kg or
more) even if the order is for less than 10  kg; opening and breaking down
the package is simply not  interesting for them.  Large manufacturers order
tons of a  given material at a time, and enter into long-term contracts; they
therefore benefit from significant price discounts,  which are not available  to
small African  manufacturers.  Payment terms are often not advantageous,
since foreign exchange  shortages often cause delays in  payments which the
suppliers factor into their prices.  Another problem was the lack of price
information for most pharmaceutical raw  materials and intermediates,  which
suppliers were quick to take advantage  oL The recent establishment of the
Pharmaceuticals  Market Intelligence System  by WHO should help improve
the availability of price  information for a limited range of basic inter-
mediates used  in production of essential drugs
Other foreign exchange  expenditures need to be taken  into accounL
In many  countries, packing  materials are imported, as is the machinery used
in production and quality  assurance; spare parts, repair, etc. must be paid
for in  foreign exchange. Elecricity production and water  purification may
require imported fueL Training  of staff and expatriate management  staff are
often provided from abroad and paid for in foreign exchange. Technology14
may nave to be purchased, espedally when patents or license  arc involved.
An effective  export strateV means that a  network of distribution points and
agents must be developed and maintained;  advertising  is another expenditure
which  requires foreign exchangc (Foster,  1989)  The case for  foreign
exchange savings, therefore,  has to  go well beyond  the  import of  raw
materials and intermediates
A  third  assumption was that  employment would be  created.
Unfortunately, pharmaceutical manuhfcture is not labor-intensive; it rather
requires small numbers of highly  skied  technical workers-the  type of
worker which is must scarce  in developing  countris.  Management skills are
also  of capital importance and are vety scarce in Afric  Creation of a few
hundred jobs may in fact cause the average  consumer to be wors  off, in
Aeat,  a  survey of  the  phamceutical  industry,  conduded  that
'Subsdizing  domestic firms through high drug prices can have negative
socal effect  In a ountry  with ...drums  accunting  for  about 40% of the
peonal  health budget, a uniformly high  price for pharmaceuticals is a
burden  which  fas  heaviy  on  the  poorer  sectors of  the  population.'
(.UNCTC,  1984.)  If it  results in higher drug prices, therefore, creation of
a few poorly paid jobs can have a negative  impact throughout the economy,
and especially on  those outside of the formal  wage-earning  sectors.
A fourth  assumption was regarding the nature of the  markLet.  It
u  thought that it would be possible to become 'self-sufficient' on the one
hand, and that it would be  possible to export to neighboring countries on
the other.  The fact that only a small range of lbs  than 40 products  (in
many ases even fewer) are produced by most factories  meant that on the
oe  hand, they were not able to produce  the ful  range of 250-300 drugs
needed for health care, and  on the other, that their *neighbors' were to a
large  extent  producing the same limited range of simple products  The
self-sufficiency  argument largely ignores the  fact that raw  materials and
intermediates are imported in any case.
A final assumption made by many firms is that they can  become
profitable by producing a wide range of products.  Since the patents for
most essential drugs have expired, profit margins are usually  quite low and
price  competition  is  stif£  In  order  to  overcome this  constraint,  a
'mixd-product'  strategy is often adopted by local firms, which produce both
esential  drugs and other drugs (and  possibly  cosmetics) for which demand
and profits margins are  high.  UNIDO has in the past recommended this
strateV  to  countries planning to  produce drugs locally.  Unfortunately,
however, the result is often that the non-essential products  made are of
little or no use; they may even be harmfuL  Health goals are therefore
sacrificed in favor of industrial  development and commercial goals.
How can public health and commercial  objective both be reached?
The guiding  principle should be a pharmaceutical version of tae Hippocratic
oath.  *do no harm'.  This kads  to several possible 'mies',  ranging from
the idal  to the  unacceptable, s  follows:15
1.  Produceaoo  esmential  drup:  this strategy avids  wastage of
forein  exhange on products witbout thempeutk  benefit  Te
disadvantap  b that profitability  may remain  low  and therefore
endanger the exstence  of the firm.
2  Produce esential  drugs and non-drug Items, such a  wsmetica,
hair tonic, toothpaste, skin lotions: If consumem  demand these
items, some foreign exchange savings  may be posible  and
profitability may  be  high, permitting  subsidization of  the
esential  drug  lie  by sales of  non-drug item.
3.  Produce both essential and non-essential drugsp:  Tis  strategy,
in fact in common application, presents a real  danger that the
non-ssential  drugs are used as substitutes  for appropriate,
effective  therapy or as expensive  placebos  Foreipn  ochrnge is
also wasted  on dubious products It is partkularly unacceptable
to  produce  drugs which are  dangerous,  either  in  and  of
themsehe  or because of their  mode of administration, Le.
injectible vitamins, liver  extrct,  etc.  A number of products
which have been removed from the market for safety reasons by
their original multinational manufctu  are still being made
and sold by  Afian  firms-becuse  they are highly profitabl
It  should be possible to meet both public health and industrial
dvelopment  goals without endangering the health of either  the
population or the enterpris.  (Foster, 1989)
When  all  the  problems and  disadvantages of  domestic  drug
productin  in Afcn  countries are wghed,  it would  be  asy  to become
pessmnistic about the  future prospects.  Tere  is no  denying that  the
obstacles are numerous, and  that past experience has been mixed at best
Recent price  trends have dealt a severe blow to local production efforts
Yet there are types of production which are likely to be  economically  and
financialy  feasible in many African  settings:
*  Local packaging  of bulk imports: This is an area which has  not
received the attention  it deserves  It  employs  unskilled or
semi-sklled labor, takes advantage of local  packing materials,
permits labelling  in local languages  and  packing  in prtet  'ldtso
or course-of-therapy packages if  this is desired.  At  the same
time the countzy  can benefit from low  international bulk generic
prices
*  Production of intravenous fluids:  Ths  may be feasible  both
economically  and technially, especialy in view of the  high cost
of shipping the products and the relative abundance of the main
raw material-water.  The technology is widely  available. Often
the main problem is the  packaging,  since imported plastk bags
are vely expensive.  Problems  with quality asurance  must not
be minimized  however, since in this area more than  others,
quality  problems can easily prove fataL16
*  Oral rehydration salts:  'hese can often be produced  locally-,
again the question of high shipping costs relative  to the cost of
raw materials and packaging  makes it likely to be economically
attractive in many African settings
*  Formulation of simple preparations such as ointments, creans,
syrups, and so on: This can be done locally with  semi-skilled
staff using widely  available technology and  possibly  some loa
raw materials as welL
*  Bilateral and regional production and quality control:  These
types of  rrangement could be made in many more  instances
than bi the present ca.  More could be done to  rationalize the
we of existing production capacity. This,  however, requires a
high degree of political will and  cooperation.
*  Procurement  of  raw  materials, intermediates,  and  packing
materials:  This could be done, by UNICEF or some similar
,rganization, for sale to developing  countries.  This  combined
with  raw materials price information now available  from WHO
would  most likelr result in significant price reductions for these
items,  which in some cases, could make existing  plants econom-
icaily viabl.
The objective of domestic drug production should be to  get good
quality, tberpeutically  useful drugs  to the people  who noed them at prices
they can afford. It should not be to  enhance national prestige, or to achieve
self-sufficiency, or  to generate employment, although all of those things
might be desirable.  If domestic production can provide good  quality,
low-price drugs, all to the good.  If not, it is  probably better to buy drugs
abroad as cheaply as possible,  package them locally--and choose another
sector to lead  industrial developmenL
Procurement
Whether there is a local pharmaceutical industry or not,  procure-
ment of imported drugs will have to be carried out  for at least part of the
drug requirements  Experience has shown that procurement is the area in
which the geatest  savings are to be made.  A procurement evaluation in
Mozambique for the ten drugs on which the most foreign  exchange was
spent showed that the difference  in total  acquisition cost represented by the
price differentials  quoted was more than $3 million, or 25% of the total
annual  expenditure on  pharmaceuticals (Marzagao and  Segall, 1983)
Similarly,  bulk purchasing  of carefully  selected essential drugs was estimated
to be able to  save  nearly 40% of the  annual drug bill for church health
institutions in Kenya-a  total of $700,000 in 1985.  (Hogerzeil and Moore,17
1967) In Central America,  an Essential Drugs Revolving  Fund (FORMED)
financed t4e joint purchase of drugs valued at USS1.3 million,  which would
have oost  USS3.8  m at prices previously paid by those countries the average
saving was 64% and  the  range was from 26% (Costa  Rica)  to  75%
(Guatemala). (Anon.,  1988a) In the Yemen Arab Republic, an estimated
20.30%  could  have been  saved  by  improved procurement  ant  drug
quantification.  (Van Haperen, 1988)  And when six Eastern  Caribbean
states established the Eastern Caribbean Drug  Servis  (ECDS), prices of
the top 25 pharmaccuticals in the  region were reduced by an average of
44%, with reductions  for some countries as great as 66%. (Management
Sciences for  Health, 1988)
A  carefully designed pocurement  strategy can  free  up  very
signfflcant  funds which can then be applied to the  purchase of more drugs.
In the discussion which follows,  only drugs are considered; however, in a
numter of countries  non-drug items (dressings,  radiological supplies, etc.)
take  up as much as a third of the total drugs and supplies bill.  Special
care is also called for in procuring and using these  supplies.
In developing  a procurement strategy,  a quantification of drug needs
can be very usefuL  A ranking by value will probably show that about 25-30
esential  drugs account for  half or more of the drugs bilL  Therefore, if
aperienced  procurement  staff are  scarce, procurement efforts should
concentrate  on  getting  the  best  price  possible for  these  high-value,
high-priority items, and in making  sure that the  quantities are appropriate.
A number of possible procurement methods are available, and most
procurement strategies will use a mixture; it is in  getting the mixture right
that significant  savings  are possible. Possibilities  range from direct purchase
of brand  name drugs from the manufacturer to international  competitive
bidding for generic drugs. Decisions must be made regarding the following:
*  whether to purchase by brand name or generic name  (interna-
tional non-proprietary name, INN)
*  whether to purchase directly from the manufacturer,  through
competitive  tendering (either local or international), or from an
international procurement agency
*  whether to purchase locally, either from a local importer  or a
local facory,  or to impor.
Each has advantages  and disadvantages,  which are reviewed below.
Brand Name or Generic?
Generic drugs are significantly  less  expensive  than their brand-name
equivalents.  Furthermore, quality need not  be sacrificed in order to take
advantages of these lower  prices.  A study comparing prices indicated that
the  brand  names were about  5 times more expensive than  the generic18
equivalents  (Szuba,  1964) Simlilarly,  a study  of the pharmaceutical  market
in Thailand  showed  that for 18 commonly-used  pharmaceuticals,  the average
brad  name  drug was  5.4 tmes more  expensive  than the  generk equValknt;
for ampicillin,  the range  was  175 times  more crpenMive,  and for reserpine
275  times  more expensive.  (Sepulveda-Aharez,  1985) Sri Lanka  procure-
ment  authorities  found  price ratis  of brand name  drup to generls of 2.2
for  mltremo  e,  10.2  for propranoloL  and 62 for  diazepa  (Jayawardene,
1980)
Another experiece, from Mali, shows  the potential  pins  from
concentrating  procurement  improvements  on high-value,  high-priority  dru
and from buying  generi.  Injetible ampicklin  represented  about 30%  by
value of  drugs consumed  at a large health center, and was widely  used
througbout  MalL The price being  paid for a brand name ampicillin  wa
23-3 times  the international  price. As a  result,  if the procurement  strategy
could  be chanpd for this one drug alone,  it would  be posble  to sav from
15-20%  of the drugs  budget.  (WHO, 1965) A simila Result was  found  in
anoter  Aian  country,  where cOe  author estimated  that use of generics
oDuld  sive 30% of the total  drug budget.  (Yudkin,  1978)
Competive  Bidding, Drect Purcuse,  Or Purchasing
Agency?
International  competitive  bidding  is often thought  of as the most
effent  and cbeapest  way  of procuring  drugs.  For large  countries,  and
depending  on the volume involved, this is probably  cortcL  However,
orpnizing competitive  bidding  requires  special  administrative  skills  and a
knowledge  of the international  pharmaceuticals  market  which many  of the
smaller countries  lack and cannot be expected  to  develop. A solution,
especially  for smaller amounts of  essential,  generic drugs, is to use a
not-for-profit  international  procurement  agency  (UNICEF  Supply  Division,
International  Dispensary  Association,  ECHO, etc.) which  does  have the
specialized  skills  required,  and which  uses international  competitive  bidding
for its own purchases.  These  agencies  buy such large quantities  of drugs
that they  obtain very low prices, and their operating margins  are very
modest. They  provide  an attracive alternative  to international  competitive
bgddin  Their main drawback  is  that they require payment  in foreign
exapnge eitber upon delivery,  or in some cases,  upon placement  of the
order.
Direct  purchase  from  the manufacturer  is rarely  the most  economic
type  of procurement,  and should  probably  be used  only  for drugs  which  are
absolutely  essential  and available  from no one ele.  LesS  than 10%  of the
drugs  on  the WHO Model  List  of Essential  Drugs  fall into this category.
It may  be possible  to drive prices for brand name drugs down  by using19
competitt e tedierng  ratber than direct  purchase a teater  isued by Mall
mrulted  reductions of  about 40% for the same brand name drugs it had
been purchasing for year  Negotiations are  lo  poible,  and a  few of
these  endtial  drug  still under  patent  (paziquantel,  for cumple)  are
avaiable at preferatial  prices througn WHO and UNICEF.  If a country
is doing sigpnifcart  amounts of direct purcbase, it seems likely  that  as much
as 10-15% could be saved.
Specal mention needs to be made of the credit  acilities offered by
some brand-name manufacturers  to verv poor countries with  poor repayment
rewrds  Ths  credit is sometimes offered with the bacing  of the exporting
countrys  gvernment  and the promise of a  buil-out  if  payment is nver
made. This credit is extremely  expense,  and can add as much as 200-300%
to the already high prices of brnd-name  drus.  A number of countriea are
usin  this  type of source because they have no choice since no one else will
seU to them; but this  s rrely  eonomicaL  Few will ever be able to pay off
their accumulated debts to these  supplies  Countries which are in such
poor fanim  l shape  that this is the only type of supplier which they can use
neod special  istace  in getting their finances  straightened out and  in
rtionalizing  their drugs policy.
Drg  donations and tied supplier credits another set of  problems.
Doato  are often made of usekss  drug,  or  drugs  near expiration.  In
lmos  all cses  they are  overalued.  In some countries the drug importing
agny  must pay customs fees (a  much as 35%  in some countries) and port
hading  charge  (typically  5-10%) on the declared value of  the donations.
-l-d  credits impose limitations on which  products may be purchased and
what prices are paid; and  prices are often excessve.  In one West African
ountry  which relie  heavily on donations and tied credits, donated  drugs
and the  purchaed  with tied credits cost up  to 9  times the prevailing
intemational  prices.  In addition, in  this country, some 40% of tbe drugs
budget is transferred to  other parts of the government in the form of port
fees, bank  fees, and customs duties.
Local Purchase Or Import
In some cases, purchase of locally  produced drugs from a domestic
manufacturing plant  can be  economically  attractive, especially if they
compete with foreign  manufacturers and win competitive tenders.  Some
countries alow lal  producers a 515% price differential in tenders; World
Bank tender procedures allow a 15% margin tO local  suppliers of most
goods  At price differentials above 15-20%,  however,  the tradeoff between
encouraging loal  industry and  -eating 15-20% less patients with a given
drugs budget begins to be troublsome.  The number of people  provided
local employment  is usually  insignificant  compared to the number of patients
denied proper treatment due  to  higher prices
Lol  purcha  of imported drugs poses a completely  different set
of problms  Price differentials  are often significant  and represent pnmarily20
the  profit margin  of the  importer. In some countries,  private imponers
have better  access to  foreign exchange than  the government drug
procurement  agency.  Failure to allocate foreign exchange, and poor
estimation  of needs may  result  in costly  local purchases  of imported  drugs.
In LUberia,  local  purchases  accounted  for up to 75%  of total purchases,  and
on average, they  cost 13%  more than imported  goods  lbe  extra cost was
estimated  at $150,000  over three years  on a total drug purchase  of about
S3,230,000,  or about 5%  of the totaL (MSH,  1984) Similarly,  in the Yemen
Arab Republic,  a review of procurement  conduded  that localy produced
drugs were 2-5 times more expensive  than the imported  equivalents,  but
that due to foreign  exchange  shortages,  the government  had  nevertheless
been obliged  to purchase  loally. (Van Haperen, 1988)
In Serra  Leone, loal  purchases were even more costly.  A
comparison  of local  prices  with  overseas  prices  for a specific  range  of drugs
revealed  that the local  purcbas  would  be 2.3  times  the  cost of the identical
drugs, imported.  Some drugs  were as much  as 10 times more expensive
oalyt.  Similarly,  local purchases  of Le 24m  could have been bought
intaationally  for Le 883,500;  local  purchases  result in payment  of a
premium  of 2.8  times the  import price. (Africare,  1984) Savings  of 5 to
15%  ar  frequently  possible,  and depending  on the local price levels and
the amount of the drugs which are being purchased locally,  could be
signiffcantly  higher and possibly  as much as 50-60%.
Storage  and Dishibution
Drugs are wasted during storage  and distribution  in three  main
ways:
*  they  deteriorate  due to I  or storage  conditions  (excessive  heat,
moisture,  light, etc.)
*  they expire due to poor needs estimation  or poor inventory
control and management
*  they 'grow wings' and disappear  either through pilferage by
employees,  theft by outsiders  who  break in (or simply walk in
due to Ix security),  or are lost during distribution  to lower  level
facilities.
The typical  structure of a drug import and distribution  system
invohes all drur,; transiting  a central warehouse (often called 'Central
Medical  Stores' e r CMS)from  where they  are distributed  either to regional
stores  or to depots at regional  hospitals.  From  there,  the drugs  are typically
distnbuted  to lower  level  health facilities.  The potential losses  are greater
at higher  points in the system,  and  highest  at the central medical  store.
If all drugs pass  through the CMS,  and if  osses are significant  at this21
point, then fewr  drug  are available for distribution to  lower levels, whose
importance (and responsibility)  is correspondingly  diminihed.  One author
esmates  that in Cameroon, 35% of the medicines  are lost from the central
medi:al stores due to poor storage conditions and expiration  due to poor
inventory controL (Van der Geest, 1982)  The importance of a well-manag-
ed,  efficient, secure  Central  Medical  Store,  therefore,  can  hardly be
overstated.  The CMS  is the place to begin if one wants to have a major
impact on  the drug supply situation.
Drugs are fragile  chemical  substances and as such need  special  care
and handling.  They must be protected from  excessive  heat and moisture,
and from infestation by insects  and other pests.  It is surprising how many
modical stores  have leaking roob,  and no  ventilation, or  are otherwise
unsuitable  Some countries are forced to store their dcogs outdoors.  This
state of affairs is aU the more surprising  when one considers the value of
the drug  which are stored  at any giVen  time; if a country's annual drug.
budget is S5 million, then at any point in time, it is likely that as  much as
$2.3  million  worth  of  drugs is  stored  in  the  central  medical stores.
Investment  in  creating  proper  storage  conditions  could  under  some
cirumstances repay itself virtually overnight through reduction of waste due
to poor  storage.  Under the worst imaginable  conditions, wastage may run
to 25% or more.
ses  due to expiration of excessive  stocks are  another  matter.
The remedies are better inventory  control and proper quantification of drug
nees,  and in som.  cse,  removal of a  corrupt officiaL  The range of
potential  koses due to  expiration is quite  significant, with as much  as
25.30% having  been reported. Ecessive and repeatea  losses and write-offs
due to cepiration should lead the  authorities to look for possible fraud in
procurement,  specifically,  for a pattern of over-ordering of certain  drugs,
perhaps from the same manufacturer.  In such a case  the loss is double;
first, the country pays much too high a  price for the drugp, and secondly,
the drum. cannot be used  and expire, so the money spent is completely
wasted.  In a  country with a limited drugp budget, this wiUl  cause many
people to be deprived of needed drugs.
Security problems  are difficult  to resolve Dmrugs  are highly  portable,
easily concealed in clothing, and  they have  a  high market value. The
incentive to steal is great, and  where  there are no counter-balancing security
measures or  penalties for infractions, it is not surprising that very  high
percentages of drug stocks are pilfered. The  theoretical upper limit to the
losses is 100%-it  is  possible for all of the drug.  to be stolen.  More
typically,  losses from central stores are estimated at  20-25% but it is difficult
to get accurate estimates. Losses from lower level health facilities are also
geat;  estimates  have been made that in Cameroon, as much as 3040%  is
withdrawn for private use by health staff. (Van der Geest,  1982) In Kenya,
implementation of the 'kit system"  whereby  drugs were packed in sealed
boxes for distribution to lower  level facilities, resulted in a reduction of
losses during distribution from an estimated 25% to less than 5%. (Ministry
of Health, Kenya, et  al, 1984).22
Improving Prescription
Major  savings  can  be made  by  improving  prescription  practices,  but
progress  in this area is slow. Prcribers  have  strong  opinions  about drugs
which are influenced  by  their medial  training and colleagues,  patient
expetations,  and not lat,  the efforts of the pharmcutial  industry  to
encourage  them to prescribe  newer, more expensive  drugs.  There are,
however,  indications  that if the prescribers  are fully  involved  in the selection
and quantification  process, and if they have experienced  a situation of
helpkuncs  due to lack  of  even  basic  eenXtl  drugs,  they  are often wiling
to change  their prescribing  behavior.
Ibo potential  pitsfrom  improved  prescribing  are enormou. Much
of what  ha been  said about  secion  above appLies  to prescription;  whereas
selection  ki  done  DUectively,  by  a group of prescnbers  who  have  both the
helth  of patients and the coUactive  health of the  community  in mind,
prescription  i  selecion of drugs  done  on an idividual basis  by a single
prescriber.  Yet too often  the prescriber  fails to take accunt  of the
ecnomic  circumstances  of his patient and of the community.
Reducing  overprescription  may be a major field for  potential
savings In Mall,  for example,  a survey  found that the average  prescription
conaia  10 dru;  it may  include duplication  in the form of the same
antibiotic under  different brand names  In most cams the patient in
quetion really  needs  only one or two  drugs,  and if the average  price of al
the druo is roughly  equivalent  (which is not usually  the case,  but for the
sake  of illustration  we will  assume  it to be so), then a 10.drug  prescription
represents  a potential  waste  of 80-90%.  In fact,  however,  :be  patient  seldom
recves  all 10  drugs  since  neither the health  services  nor his own financial
situation permit this  extravagance.
Experience  shows  that a realistic  figure  for savings from improved
prescription  may  be on the order of 60-75%. A  study in Ghana in 1980
examined  prescriptions  at several  health  centers  and found  that 96%  of visits
were treated with at kast one injection,  and that an average  of 3.9 items
was gien on each prescription.  When  actual prescriptions  from a number
of health centers  were compared with best practice' for the condition  as
established  by the  health authorities,  the drugs  cost would  have  fallen by
70%. (Barnett,  Creese,  and Ayivor,  1980) Alternatively,  approximately  3
times as many  patients could have  been  treated for the same budget
Similarly,  in Nigeria,  of 299  cases  of diarrhea,  poor prescription  and
over  of antibiodta  resulted  in a wastage  of N2526,  or 97%  of the amount
spent on treating the  cases  Similarly,  prescription  of a brand name
antibtic  which  was  three times  more  expensive  than a generic  which was
also availabk,  resulted  in an estimated  over-cxpenditure  of 78%. Despite
the fact that 7 of the 11 doctors  at the hospital  knew  that the brand name
wa  more expenshe, they  prescribed  it in 77% of cases  Curiously,  the23
brand name  drug wa judg#d  to have been used unnecesarly in 82% of
cai,  whle the pneric  was used unnecsurily  in only 13%  of cases.
(seaumbe  and Oviawe, 1988).
Other posible savin  would  result  from  the use  of fewer  injections;
not only  are Injectible  forms signicantly more  expensie, they  also require
the purhae  of syringes  and needks. Sterilization  of injection equipment
require fuel  and tkes  up te  of the health staul Inadequate  sterilization
now  carie  the added  risk of tansmitting AIDS;  the costs to the patient
and his  ful,  and to society  of a case  of AIDS are difficult  to  calculate
at thi  pOinL
In recogition of the fact that private sector  drug  sellers are de
Ikto  preabe  of drus  a  well as seles,  there have been  a number  of
initiatve  to  improve  their prescribing  sllt  In  Nepal, a  training
programme  wo provded for the drug  sellers  and a prescribing  manual was
producd.  IitW ly there wa some resi tance ad  suspicion  on the part of
the drg  sllkrs, but eventualy they  came  to appreciate  the progamme and
to takes  an ative  part  In Ohana,  a contraceptive  social  marketing  project
(SOMARC)  provided  trining  for drug sellers in the  prescription of
contraceptives,  induding  the oral contraceptive  pill,  and similarly  a manual
wu producod  Such  progrmmes could  be a viable  way  of improving  the
presripton  and use of drugs in Africa  However,  the  question of the
ilegalty of these activities  might need to  be addressed  prior to actual
mplementation  of such programmes
Overprescriptionand  inappropriate  prescription,  includingexcessive
ue of injectables  and antibiotics,  can represent  a major  source  of wastage
in drg  suppliL  Efforts to involve prescnbers in drawing up and using
standrd treatment  shedules can be effective  in reducing  overprescription,
and can save as much  as 50-70%  of the  drugs  bilL
Patient Infomation  and Compliance
When the patient finally  gets his drugs, does he take  them as
intended  by the prescriber? Evidence  from industrialized  countries  shows
that complance  is, on average,  about  50%-only  half  of patients  take drugs
as  intended. There is reason to expect that the situation is  worse in
developing  countries,  given  the lack  of instructions,  low  Uteracy,  dispensing
practices  which  may involve  simply  handing  the patient some  pills  without
explanaton,  and so on. Efforts  to improve  dispensing  practices  and provide
information  to patients  regarding  dosage,  mode  of administration,  and  so on
are being undertaken  in various  countries  and although  most have  yet to
be fuly evaluated,  it seems  that they  can make  a  difference  in the way  the
patieons  we their drug.  Too often this last link in the chain  is forgotten;
the  prescriber  and dispenser  breathe a sigb of relief that the  drugs  have
reached the hands  of the petient, only to learn that he has thrown  them
away  upon kaving  the pharmacy  or simply  stashed  them for  another ilness24
Efforts  at building  trust between  prescriber  and patient,  and in explaining
the use and administration  of drugs,  and in improving  patient information
and dispensing  prctica,  can be useful  in improving  patient  compliance.
The impact  of the price  of drugs  on compliance  should not be under-
estimated. In a study in Nigeria,  It was found that when the cost of a
prescription  was NI-9, it was filed  in 83% of  mues.  But when the cost
exceeded  N20,  tbe rate of filling  dropped  to 21%.  (Isenalumbe  and Oviawe,
1988)
Table  S. Estimated  Potential  Savings  from Rational  Drug Use
Average  highest
(Percent)  (Percent)
1. Selection  using  cost-effectiveness  criteria  10  60
- Quantification  as basis for ordering  15  30
3. Procurement:
a) use of generic names  25  30
b) use of competitive  bidding  procedures  10  15
c) direct import from low-price  sources  5  15
4. Storage  and distribution:
a) proper storage  conditions  10  25
b) good inventory  mgt and low  expiration  15  20
c) reduction  of theft and pilferage  20  60
5. Rational prescription  50  70
6. Improved  patient xmpliance  20  25
Sources: See text
Sunmary of Potential Savings  from Improving Efficiency
The previous  discussion  has pointed  up possibilities  for significant
savings  in most  areas  of drug  supply  management  and use. Potential  savings
from  individual  rationalization  measures  (summarized  in Table  5) range  from
10-60%  or more. The biggest  gains  appear to come from better procure-
ment and better prescribing.
Each  sub-optimal  decision  has  a cost,  and as drugs  flow  through  the
system,  poor decisions  successively  reduce the  value of drugs left in the
system  The most costly decisions  are made  at the top.  A procurement
official  can make  a decision,  for example  to purchase  using  brand names,
which costs $5 million. A decision  made  by any one of 5,000 individual
prescnibers  will  have  only  a limited  impact  by i,self.  Cumulatively,  of course,25
if all prescribers make  the same poor dacsior,  the effect Ii te  same as a
poor  decision at the top.
Special  Issues  in Drug  Supply  in Africa
Geographic  Factors
Comparisons are often made between African countries  and such
countries as Thailand or India, with the  implication that what is feasible in
Thailand should be  feasible in Africa  But the geographical situation of
much of Africa is quite different and such factors as land use  patterns, the
distr.bution  of the population, and  their  income levels clearly have an
impact on service delivery and  logistics.  The average cost per person of
providing service rises quickly as more remote areas are reached.  (Over,
1986)  This is often a particularly strong  constraint in African countries
where low rainfall and  consequently extensive  agricultural techniques have
produced  low population density.
Table 6 shows  the differences  in population density between  several
oDuntrie  Assuming  that 90% of people said to be part of the agricultral
work force are livng in areas desinated  as agricultural areas (the remaining
10%  are  asumed  to  be  living on  marginal lands  not designate:'  as
agricultural), in Mall, for example, population density  wou1d  be about 20
penom per square kilometer in  agricultural areas.  In Zambia, it would be
12  Kenya,  with  263,  is atypical of Africa in many ways and is more like
some of the Asian countries, its agriculture is in general  more intensive,
some of the land is very ferile,  with  abundant rainfall, and much of the
agriculture is on  plantations or large cooperatives.
By comparison, i.n many Asian countries, such as  Bangladesh,
agriculture is highly intensive  with very small  plots farmed by an individual
fanner, perhaps with landless laborers as well,  resulting in a high  density per
square  kIlometer even in rural areas.  In Bangladesh rural areas  have a
density of over 720; in Thailand the density in  agricultural areas is about
183, and in India and Indonesia,  about 270. Clearly the costs per person
served26
Table  6.  Population Density in Agricultural  Areas in Several  Countries
(a)  (b)  (c)  (d)  (e)  (1)  (g)  (h)
Total  (JNP/  Pop.  Area  %  % of  % of Density
Pop  capita  density  (000  urban  land in labo,  irn  agric
(1986)  (1986)  overall sq Ian)  (1986)  agric  agric  areas
(millions) (USS)  (pop/
sq km)
Zambia  7  3W  9  75Z  48  S3  73  1Z
Mali  8  180  6  1240  20  25  86  20
Mcxico  80  1860  41  1973  69  50  37  27
Thiland  53  810  103  514  18  36  71  183
Kenya  21  300  36  583  20  10  81  263
India  781  290  238  3288  25  55  70  272
Indonesia  166  490  87  1919  25  16  57  277
BangladeshlO3  160  715  144  18  67  75  721
NB:  The assumption made was that 90% of t!le labor force workcing  in
agricllture  lives on the part of the land designated as agricultural,
e.g. (a x g x 0.9) - (d x f).
Source:  Data from World Development Report,  198&
are much  higher in an area with only 12 persons per  square kilometer
thanin an area which has nearly 700. An area with high population density
Is also more likely to have a  well-developed  road system  and transportation
infatructure;  tadis,  private trucking firms,  and other  transportation is more
often found where a  population exists  to support these businesses.
The implications of population density for costs of service delivery
are significant  as well.  If for example one wanted to distribute antimalarial
drugs to people in  agricultural areas, in Bangladesh about 9000 people
would be2 found within a  radius of two kilometers from a central  point
(3.14 x 2  km x 721 persons/sq km).  In India, Kenya, and  Indonesia, one
would find about 3200 people; in Thailand,  about  2400.  But in thinly
populated rural  Mexico one would  find about 300, and in Mali and in
Zambia, less than 200.  Therefore, to reach 10,000  people with antimalarial
drup  within a 2 km distance of their home, one would have to  establish
45 times as many distribution points in Zambia as in Bangldesh.  Delivery
costs per person reached would of  course be 45 times higher.  More likely,
one would hold  down costs by expecting people to walk a greater distance,
for example S or 10 km to the distribution point in less  densely populated
areas.  Tbe success of the intervention would then be highly  dependent on
the value people place on  the intervention, and the time and travel costs
they  incurred in travelling the extra distance. (Foster,  1987)
For Africa, this  means that costs of drug supply (and  of other
services)  are significantly  higher in rural areas, and many  of the models tried27
in otber pars  of the world  wW be too costly.  The Thai drug banks, for
example, require an intensity  of supervision  and supply  which is not feasible
in Africa due to the higher costs of  transportation.  rraining of mothers to
use ORS by health  educators travelling on foot, as was done in the BRAC
projet  in Bangladh.  would not be feasible in rural  Africa  Other modes
of transporttion  need to be envisioned;  for example,  motorcycles  with small
trailr  might be suitable under certain circumstances  Paying individuals
to use their private transportation to come to a  central point to collect
druos may be more wset-effective than  maintaining an outward-reaching
delivery capability.  The cost of collcting  money recovered through user
charge  will be much higher than would be the case in Asia, and  might
prove prohibitiv  Other types of senvice  delivewry  need to be developed for
ural Afica, and the constraint of low population density needs to be taken
into account when  planning health services in generaL
Coun  eit  d&ugs
Counterfeit drugs are a growing  concern in a number of  countries
around the world, including  several in Africa. A  counterfeit (or 'spurious'
or'  kel) drug is one which is  not what it is claimd  to be.  It may contain
too little of  the  actve  ingredient,  no active ingredient at  aL, or  be a
differnt  drug entirely from what it is purported to be (chloroquine labeled
as quinine, etc.)  Such products are  often imitations of well-known  brands,
using the same atrade  dress', ie.  packaging,  capsule color, etc.; faking the
drug  ts  advantage  of the market share and promotional success of the
original drug.  In other cases, they are substandard  copies of established
pwducts, whkh fail to meet the  requirements of the established product.
The most dangous  type of faking, however,  is when the drug in question
contains substances  completely  different from what they  are purported to be.
They may contain starch, baby powder, etc.  Another type of faking is the
frudulent  alteration of  expiry dates on expired drugs. (Igboechi, 1988)
Typically they are distributed by unregistered drug sellers and  through
market traders, although registered premises have also been found stocking
and dispensing such products,  sometimes unwittingly.  (Atueyi, 1988)
Counterfeit drugs are manufactured in many parts of the  world,
induding developing Asia and Africa; and there are  European sources as
welL One investigation agency estimated in 1985  that 'fake drugs are now
a billion-dollar industry.' (Hall, 1985) Within a few hours of his arrival  in
a European city, an investigative  reporter was able to establish contact with
three companies supplying counterfeit  drugs.  The sources offered to fll
capsules with inactive  ingredients to  look  like the real  products; they
produced  samples and a price list, and stated that they could provide  one
millon  tablets of several drugs within six weeks  Prices were approximately
one-fi  to one-tenth those of  the real products A sample which  was later
analsd  was found to contain 232 mg of the active ingredient, not 400 mg
as stated on the label; and it took 105 minutes for the  tablets to dissolve
compared  with  15 minutes  for the  original  product,  making  the  product
Inefftive  (Mahmood,  1987)28
At the World Health Acisbiy  in May 198  a number of countries
eressed concern about counterfeit drugs which  were circulating on their
markets. Tese  are primarily  drugs which are manufactured clandestinely
and marketed with the connivance  of unscrpulous retailers*.  (WHO, 1988c)
In many cases, those involvet in such practices are not  breaking any laws
in the countries concernd;  and it is difficult to bring these practices under
the law in view of  the international basis of such transactions and  the
segmentation of operations, whereby  a drug might never transit the country
to which the  money was ultimately sent.  It  is hoped  that  the  WHO
cenifcation schem  might improve the situation, which will be kept under
review, guidelines are to be developed. (WHO, 1988c)  Concern was also
expressed  by the European Economic Commission, and the  Intemnational
Chamber of Commerce  Pharmaceutical  companies  whose products have
been  copied  ve  undertaken legal proceedings in several countries  to put
a stop to  the  practie.  (Scrip, July 29, 1985)  In Nigeria a  number of
companies have been blacklisted for the production and distnbution of fake
or adulterated drugs and are no longer eligible to supply drugs to any public
institution in  Nigeria. (Anonymous, 1988c)
The measures which can be taken against counterfeiting  include
improving  the  legislative  framework,  increasing quality  control inspections,
and prosecuting offenders  A  first step is to make sure that laws exist to
enble  the  prosecution  of counterfeiters if they can be caught.  Catching
them requires  reinforced quality  control  capabilities. But customs officials,
quality control  inspectors, and police and legal authorities are susceptible
to corruption,  and the problem is likely to persist for some  time. (Atucyi,
1988)  Unfortunately  an  African  country  is  often  powerless against
counterfeiten  operating from another country,  and while the local offenders
are caught  akd punished, their uverseas  correspondents are untouchable.
A  more likely outcome would be that pharmaceutical corupanies  whose
products  are  being copied will take  measures  to  halt  the  traffic  in
counterfeit  drugs which is clearly against  their interests.
Futancing  Essentia Dnugs
The simple response to the complex problem of shortage  of drugs
in rural areas has recently been to propose that  people in rural areas pay
for drugsL  In particular,  UNICEFs Bamako Iniliative  has proposed that
MCH services  would be financed in rural areas by sale of essential drugs
at two or three times the cost price. (Anonymous, 1988b)  There are many
problems  with this proposaL  Equity would in  all likelihood fall by the
wqyside,  as services would be  priced weil beyond the means of the poorer
income groupL  A  recent epidemic  of malaria in Madagascar is reported to
have  kdlled  a large number of people (as many as 100,000  according to
some reports) and although there was chloroquine available,  it was out of
reach of some of the  poorest segments of the population. (Anonymous,
1988d)29
The management implications of cost recovezy  schemes  are con-
siderable and there  is little evidence that they have  been studied in the
ncesary  depth.  'Me schemes would  pnerate  only loal  currency, how
would this be converted into foreign  exchange  after the inevitable departure
of the  external donors?  In al  lkelihood,  the scheme would  encourage
inappropriate use and overprescription of drugs as  availability  of funds for
MCH and preventive care would be  cosely tied to the lvel  of drug use.
The scheme would do  little to improve the efficiency  of the drug supply
systemi
Participants in a WHO workshop on fnancing essential  drugs,
held in Harre,  Zimbabwe in March 1988 came to three  main cnclusions.
Furst, there was agreement that  considerable savings  are to be found within
the drug supply  systemn As has been shown in the dsbcion  above, the
typical drug supply system has many inefficiencies  which can  be corrected,
with significant savings to be made. The  fst  step in increaing  availability
of drugs should be to  rationalize procurement and use. Another possiblity
is to  increase resources for drugs through realocation  of health  sector
expeiditures  (WHO, 1988d)
A second conclusion  was that *cost  recovery brought with it hidden
costs, both in terms of decreased utilization of health facilities,  and in terms
of the administrative  costs such schemes entailed.  Giving drugs away free
was  much easier than charging for them.  Special care would need  to be
taken to ensure that the fee system did not disourage  vulnerable groups
most in need Lif care, but klat  able to  pay. Manaement  of the funds was
a  concern; and  when the  costs of improved accounting, transport and
supervion,  etc. were taken into account, the ratio of administrative costs
to atual  funds reuwered w  lihkely  to be less  fvorable  in rural area.
The  inequity of charging the  rural  poor while urban  dwellers
continued to receive free care was of concern as welL A recent World Bank
study suggested that a 'modest'  fee would be 1% of annual income, which
should suffice for two annual visits.  (World Bankr,  1987)  But the significant
inequality of income distribution patterns in many African  countries, with
income highly concentrated in the upper 10% or 20% of the population, is
another  cause for concern when  setting a fee.  Data for nine low-income
countries showed  that on  average, the  top quintile  had about  52% of
incme;  the second quintile, 20%; the third quintile, 12%; the  fourth
quintile, 10%; and the  owest quintile, 6% of income. (World Bank, 1985)
In Guinea-Bissau, for eanmple, average per capita  income was
estimated at $170 in 1986;  yet if income distribution followed this pattern,
the  owest income  quintile would have an average per capita income of
about  $50. Roughly half of the population would have kl  than  $100 per
year, and the highest quintile would have about  $425. If the World Bank
proposal were adopted in setting the  fee, the lvel  might be set at $1.70 for
two visit.  Such a  fee would represent over 3% of per capita income for
the  lowest quintile,  but  only about  0.4%  for  the  highest  quintie.
Furthermore, per capita income usually counts goods which are not traded
(such as home-consumed produce)  and thus not cownerted  into csh;  and30
lower income groups  have only about 25% of their income in actual cash.
(P. Gertler, personal communication) rune  costs,  travel expenses,  and lost
income are other costs which are often  not taken into acunL  Each visit
for which a  theoretical  0.5% of income would be charged, could easily
represent a  much higher percentage of income when travel costs, lss  of a
day's wages, and other  factors are taken into accounL
The statement is often made that 'people  are willing to  pay for
drugs,' the point of reference being what people  have paid in the past, and
thereby demonstrated themselves willing' to pay.  But people often make
expenditures on  drugs in what are perceived (rightly or wrongly) to  be
life-or-death situations. Since economic  barriers to seeking care are greater
for poor people, they may tend to  delay seeking cae  until the situation
really  i  life.threatening.  They  may go  into  debt  or  seU important
posa  ions (cale,  etc.) to be able to purchase drugs and  medical care in
an emergency  situation.  'Willingness  to  pay' data, therefore, must be used
areflly,  with the understanding that the poorer the person, the more likely
it  is tQat the expenditure recorded reflects an extraordinary situation-and
cannot be taken to represent an amount they  would be willing (or able) to
pay on a regular basis.  Special caution must be exercised  when using such
data to  predict revenues from or utilization of routine health  services.
Finally,  the workshop participants concluded that in view of the very
low income levels in much of rural Afia,  charging  people for drugs would
be more useful as a  rationing mechanism than as a major source of revenue.
It  was important  to be  realistic about  the potential  of cost  recovery,
experiec  with user fees has shown that in many  low-income  countries,
such fees do not contribute greatly to  revenue. Even full cost recovery  for
drugs has not been  possible to achieve in many countries.  (WHO, 1988d)
The  Bamako Initiative, which proposes to recover 2-3 times the base cost
of drugs, could disqualify  a considerable  proportion of the poor  inhabitants
of rural areas. (Anonymous, 1988b)
Impact of the AIDS epidemic on drug supplies
In countries with a high prevalence  of HIV infection,  the epidemic
represents  signfficant additional  morbidity and  mortality in a  group of
primarily young adults who were not  previously ilL  It will make demands
onA  all health resources  including hospital beds, staff cae,  and drugs, and
will make  it difficult to maintain present levels  of care for other  illnesses.
There h already some indication that other  non-HIV positive patients are
being crowded out of the health  care system in some countries. As HIV
seropositivity often  causes a  longer hospital stay, the overall number of
admissions may stagnate or decline as occupancy rates reach  or surpass
100%. The intensity of care may also increase  since only very sick people
will be able to  be admitted to  hospital, and  more care wi  have to  be
provided on an  outpatient  basis; this in turn can be expected to result in
an overall higher cost per admission and per  bed/day.31
Drugs have an imporlant role to r'.y  in the care of  HIV-positive
patients at all stage  of the disease. Many  of  the symptoms  can be managed
adequately and much relief and comfort provided with inexpensive  essential
drus.  As  regards specifc needs for drugs and supplies, for the most  part
they  are  the  same  essential  drugs  provided for  primary  health  care
througbout Ahia.  In particular, needs are for  antibiotia,  anti-fungals,
antidiarrheal  and  oral  rehydration  solutions  anti-tuberculosis drugs,
analgesi  and  antiseptics and supplies, particularly gloves
The more complex and expensive drugs such r  imphotericin B,
acydovir, experimental drugs,  and some of  the anticancer drugs, require
diapostic,  nursing,  laboratory,  and management skills which are usually
available  only at the central teaching hospital leveL As a  result, the overall
economic impact of the purchase of these  drugs may not be overwhelming,
prvidig  tbey are purchased only in quantities which can be used properly
at the  appropriate lewis of car.  The most significant economic  impact
is likly  to be caused by the more routine essential  drugs, which wili be
required  in large  quantitieL In view of  the expected numbers of new
patients,  special effort will need to be made to procure them as cheaply as
posibl,  and  distribute them widely.  Many sexually  active HIV-positive
patients are willing to use condoms both as contraceptives and to protect
thir  partnes  Provision of adequate  supplies of condoms to those who
know they are HIV-positive  and are willing to use them should be a very
high priority.  Condoms were added to the WHO Model List of Essential
Drugs in  December 1987.
Decisions will soon need to be made about what conditions can be
cared for at which lewls of the bealth  system The fact that many of the
mast commonly used drugs  for HIV are provided to rural health centers
sugets  that  with the addition of only a  few drugs, treatment  of some
manifestations  of HIV could be decentralized  to a lower level,  provided staff
were  given guidelines, training,  and  appropriate  quantities  of  drugs.
Management protocols for  HIV are urgently needed, to prevent shortages
of essential  drugs from reducing the quality of care for both HIV-negative
and HIV-positive  patients alike. They are also needed to  prevent the sense
of helplessness and frustration on the part  of the medical and nursing staff
from expressing itself in  requests for 'Whigh-tech'  solutions to the problem
and  sophisticated drugs and test kits, or in "burn-out  of  medical staff.
Realistic, feasible treatment guidelines and  protocols would do  much to
reassure staff that they are doing  as much as can be expected for their
patients.  As the  epidemic spreads, some consistency  of management across
hospitals would reduce "shopping"  and resultant double  counting of cases
since management would be approximately the  same in most places.
Conclusions
Shortages of drugs in Africa are caused not only by  lack of funds,
although in many countries this is the major  reason.  Poor utilization and
watap  of drug  in both  public  and private sectors are also responsible and32
ca  be  improved;  and the wtage  of available  foreip exchange  can  be
reducedL  Whie the private  sector  bas  a role to play, it is important  to be
realistic  about  Its  ability  to seon the wbole  population  and about  the qualty
of  the service it  provide.  L1a  producion of drup,  although a
superfically  attactive solution, needs to be wsed  realistially, takdng
acunt  of ndividual  country cicumstc  In some uss,  rehabilitation
of misting factories  is a promising  avenue. Specific  meurm  to  improve
selection, quantification,  procureent,  storage and  distnbution, and
prescription  and use of drugs have been  implemented  in a number of
Acan  countries, resulting in sigifict  improvements  in the availability  of
drugs Poliymaken need  to realize  that tochiques and experience  CDst  to
solve  or at kst  improve  mat  of the drug supply probkm  in Africa,  but
that the ieient  whkh mak  the difference  is political  will  and support
Isues for the future in drug supply for Africa,  for  whib  dear
aswes  do not yet ex.st,  indude finding  ways  to overcome Afica's
geographic  constraints;  taing steps to deal  with  the problm of counterfeit
drug;  improving  the  finacing of essential drugs without discouraging
udlition  by the groups mast in need;  and planning  for the  provision  of
drug during  the AIDS  epidemic. A spirit of opennus and willingness  to
disu  all available  options on  the part of governments  and donors  alike
will  diUitate  the  search for solutions33
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Aan  1.  EsMad  Essetiul  Drop  Coe_  In
Selected  A%n  Countrlis, 1986
Estmtad  Drug  Total  Population
Coverage  Population  Not Covered
(Percen')  (Mlo  s)  (Millions)
Angola  15  U6  7.3
Benin  15  4.2  3.6
Botwana  75  1.1  0.3
Burkina  Fao  45  8.1  4.5
Burundi  45  4.8  2.6
Cameroon  15  10.5  8.9
Central Afican  RepublIc  15  2.7  2.3
Chad  15  5.1  4.3
Comoro  75  0.4  0.1
Djlboud  75  Q4  0.1
Eq;torlal  Guinea  15  0.4  0.3
EtiopIa  45  43.5  23.9
Gabon  75  1.0  0.3
Gmbia  75  0.8  0.2
Ghana  45  13.2  7.3
Ounea  15  6.3  5.4
Guinea-BLsu  45  0.9  0.5
hvory  Cost  15  10.7  9.1
Kew  75  21.2  5.3
LAsotho  75  1.6  0.4
liba  15  2.3  2.0
Madagcar  15  10.6  9.0
Malawi  45  7.4  4.1
Mali  15  7.6  6.5
Mauritamia  1S  1.8  1.5
Mauritius  75  1.0  0.3
'  ozambique  45  14.2  7.8
;iger  45  6.6  3.6
Nigeria  15  103.0  87.6
Rwanda  15  6.2  5.3
Senegal  15  6.8  5.8
Seycheces  75  0.1  0.0
Sierra Leone  45  3.8  2.1
Somalia  15  5.5  4.7
Sudan  15  22.6  19.2
Tanzania  75  23.0  5.8
Togo  45  3.1  1.7
Uganda  45  15.2  8.4
Zaire  45  31.7  17.4
Zambia  45  6.9  3.8
Total  433.5  287.738
PNCCat  not acwred.  6
Aru=  1.  EStImaed  Esntiel  Drup  Covwme in
Seected African  Countres, 1986
(Continued)
Notes:  Coverage  estimates  from World Drug Situation, WHO, 198&
Originl document  had  three  rnges, <30%,  30-60%,  and 60-90%.  Tbhee  calculations  were made
iuing midpoints  of the ranges,  Le.  15%,  45%, and 75%.
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